Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Lung Neoplasms, Non-Small Cell Lung Cancer Clinical Trial

Official title: A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer

Status Terminated

Clinical Trial Summary

This is a prospective, single institution phase II study, whose primary objective is to estimate the median and three year survival rate of non-small lung cancer patients with Stage IIIA and IIIB intra-thoracic disease which is referred to as "locally advanced" non-small cell lung cancer (NSCLC).

Clinical Trial Description

Patients with histological documented non-small cell lung cancer, that are considered to be inoperable, meet all the eligibility criteria, and sign informed consent will be treated with one cycle of irinotecan and cisplatin, followed by three additional cycles of chemotherapy with 60 - 70 Gy of concurrent radiation therapy. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Lung Neoplasms, Non-Small Cell Lung Cancer

• NCT number: NCT02275806
• Study type: Interventional
• Source: Leo W. Jenkins Cancer Center
• Status: Terminated
• Phase: Phase 2
• Start date: October 2014
• Completion date: September 27, 2017